

ON THE CUSP

2024 IN REVIEW

CELEBRATING A DECADE

Ostrom reflects on impact, alumni, research, and future visions for CUSP



PRESCRIPTION FOR PATIENT SAFETY

CUSP research is changing how the industry approaches patient care



CHAPMAN
UNIVERSITY

School of Pharmacy

Celebrating 10 Years of Excellence

Contents

CELEBRATING 10 YEARS

- 1 Our Past, and What the Future Holds

STUDENTS

- 2 AACP Student Chapter of the Year
- 3 Student Accolades

ALUMNI

- 4 Class of 2024
- 5 Active Bystander Story, Residency Successes

PHILANTHROPY

- 6 Ralphs Commits to the Future of CUSP

FACULTY

- 7 Researcher Spotlights
- 8 Practice and Service
- 9 Under the Microscope

PATIENT FOCUS

- 10 Equity for Spanish-Speaking Patients
- 11 Pacific Coast Patient Safety Conference



Design and Content

Luke O'Connell

Supporting Design

Silas Fernandes

Special Thanks

Stace Dumoski
 Adam Hemmingway
 Chapman University Strategic
 Marketing and Communications

Chapman.edu/pharmacy

A MESSAGE FROM OUR DEAN

Chapman University School of Pharmacy had another remarkable year in 2024. Our students, faculty, and staff continued to demonstrate excellence across all areas of our mission. Our students passed the NAPLEX licensing exams at rates that rank 18th in the US and matched to residencies at rates that rank 3rd in California. CUSP made the largest upward move in the US News and World Report rankings of all pharmacy schools in the nation, gaining 19 spots.

CUSP faculty continue to make their marks on the national pharmacy and research landscapes. This report spotlights a sampling of the many accomplishments and achievements of our world-class faculty. New extramural grant funding from the National Institutes of Health, pharmaceutical companies and foundations have pushed CUSP's funding for basic and clinical science to new heights. Honors and awards from ASHP, CPhA and AACP recognize the impact of several of our faculty and highlight the prominent roles our faculty play in the national healthcare scene.

We are grateful for all the community and corporate partners who support our mission and vision. Together, we are creating a meaningful impact on the health and well-being of our communities. I am incredibly proud of the dedication and passion shown by our students, alumni, faculty, and staff. Our shared commitment to innovation and excellence drives us forward into 2025 and beyond.

Rennolds Ostrom, Ph.D



Celebrating 10 Years of Excellence

Since admitting our first Doctor of Pharmacy class in 2015, CUSP has built our research capabilities from scratch, rose up the rankings, and turned out graduates who pass the national licensing exam and match to residencies at rates higher than the national average. The school has been a confluence of strong research and student-focused teaching.

#3
FUNDING
NATIONWIDE

No. 3 nationwide for both NIH and total funding among R2 institutions (total funding in 2022/2023 was \$4.1 million).

87.9%
NAPLEX PASS RATE


In 2024, CUSP graduates had an 87.9% North American Pharmacist Licensure Examination (NAPLEX) pass rate, almost 10 points above the national average.

300+
PRECEPTORS

More than 300 practice mentors give our PharmD students a variety of learning experiences, every year of their study.

1/3
STUDENTS'
TIME SPENT IN
EXPERIENTIAL
EDUCATION

PharmD students spend over a third of their time in experiential education, starting their first year.



YOUNGEST PHARM D
GRADUATE AT AGE
19

Kassidy Vo was the youngest person to graduate with their PharmD in the state at the age of 19 in 2019.

20
SPOT RANKING INCREASE

CUSP jumped nearly 20 spots in the US News & World Report rankings in 2024

#1
PHARMACY
SCHOOL

No. 1 pharmacy school for National Institutes of Health funding among R2 institutions in California.

2x
HIGH SCHOOL
STUDENT PARTICIPANTS

Participants in our Pharmacy Summer Research Program for high school students have doubled each year since its inception in 2022.

588
GRADUATES

CUSP has had 588 total graduates since its inception.



"We have incredible faculty," Ostrom says. "Not all researchers are passionate about teaching, but many of us are. Those who are passionate are a good fit for a school like ours. They align with the teaching-first DNA of Chapman"

TOP 2%
MOST CITED SCIENTISTS

Five faculty members were recognized as the world's top 2% most cited scientists in 2022 by Stanford University.



ACCP Awards Chapman University

CHAPTER OF THE YEAR

The CUSP student chapter of the American College of Clinical Pharmacy (ACCP) was honored as the 2024 Outstanding Chapter Award recipient. This national recognition is annually awarded to a single chapter across the United States for exemplifying dedication to patient care, leadership, and exceptional professional development through membership and organizational activities.

CUSP's student chapter accepted their award with a speech at the annual ACCP conference hosted in Phoenix, Arizona in mid-October. During their acceptance, the board presented their remarkable efforts to expand the influence of pharmacists in patient care, impactful research, and education in cooperation with other health disciplines.

One of the many influential programs that CUSP's ACCP organization hosted included their annual "Stop the Bleed" event in September. The event prepares young health care professionals to learn life saving techniques during emergency situations and also features guest speakers, such as residency directors from hospitals in the area. The event also counted towards students' mandatory co-curriculum professional development course credits which incentivized greater attendance and impact. Other programs offered by CUSP's ACCP chapter included routine shadowing opportunities between students and faculty, low stakes networking opportunities, mental health social events, and passive drug education messaging.



SHAPING THE FUTURE OF HEALTHCARE

At the heart of CUSP are exceptional students who embody the spirit of excellence, dedication, and patient safety. Our students bring unique and diverse perspectives, partake in cutting-edge research, and lead by example, all contributing to tangible differences in the lives of patients and communities.



Dr. Elliot S. Vesell Award Bestowed to Amelia Monfared

Monfared was honored with the Dr. Elliot S. Vesell Award for her abstract in the area of pharmacogenomics. Given by the American College of Clinical Pharmacology, the award recognizes Amelia as a top student researcher in the area of pharmacogenomics.

Her project abstract, "Analyzing the Association Between Single Nucleotide Polymorphisms & Combinations of Buprenorphine & Associated Metabolite Concentrations," resulted from her research from the mentorship of professor Dr. Sam Harirforoosh. Melissa Hoang, PharmD candidate '25, is listed as a co-author.

Her work investigated the intricate relationships between genetic variations and the pharmacokinetics of buprenorphine, a critical medication in pain management and opioid dependency treatment. The findings could potentially influence personalized medicine approaches in pharmacotherapy.

Monfared is on track to graduate in Spring 2025.



Elyn Lam Named Recipient of ASHP Student Leadership Award

The American Society of Health-System Pharmacists bestowed Lam with their Student Leadership Award among exceptionally qualified applicants from across the nation.

Having graduated in 2024, Lam's time at CUSP was defined by her involvement with CUSP's CSHP/ASHP-SSHP chapter. Lam received numerous awards, held several national-level positions, and led the CUSP chapter to serious recognitions, such as:

- ASHP Outstanding Professional Development Award (2021-2022)
- CSHP Community Service Project Award for Community Outreach focused on Mental Health Awareness (2023)
- ASHP Pharmacy Student Forum

Since graduating with her PharmD at Chapman University, she has continued her education at University of Michigan Health for their PGY1 & PGY2 Program in Health-System Administration & Leadership, with a Master's Degree in Business Administration.

INTRODUCING THE CLASS OF 2024



Inna Tagarino

APEX '21, PharmD '24

Drawn to healthcare and an accelerated pathway, Dr. Tagarino joined the APEx program, gaining academic preparation and valuable mentorship for the PharmD program. She found a supportive community in Kappa Psi, where she held leadership roles, built lasting friendships, and expanded her professional network. Grateful for the experiences that shaped her personally and professionally, she now advances toward her dream as an ambulatory care pharmacist, having matched with the County of Santa Clara Health System PGY1 Residency Program.

Jack Menzagopian

PharmD '24

Dr. Menzagopian received the Panther Award for his leadership, community service, and advancing pharmacy. Guided by his Catholic faith, Jack is passionate about patient care and mentoring others, serving in leadership roles with the Vietnamese American Pharmacy Student Association and the Hispanic Association of Pharmacists while earning Dean's List honors. Known for fostering community and redefining perceptions of pharmacists, he currently works in his PGY1 Residency at Loma Linda University, focusing on academia, acute care, and infectious diseases.



Judy Weng

APEX '17, PharmD '20, PhD '23

Dr. Weng has made her mark in academia. As a graduate of 2 CUSP doctoral programs, she attributes her success to Chapman's supportive environment and dedicated professors. Her time was shaped by mentorship and research in Dr. Ajay Sharma's lab and ignited a passion for discovery. Now an Assistant Professor at Marshall B. Ketchum University, Dr. Weng inspires future pharmacists, blending her clinical expertise and research skills to tackle impactful healthcare challenges. Dr. Weng earned her PhD in December 2023, and walked during 2024's spring commencement.

CHRISTINA NGUYEN REVIVES UNCONSCIOUS WOMAN

Dr. Nguyen, PharmD '22, helped a woman in her community get the care she needed in Redwood City.

Working as an ambulatory care pharmacist at Kaiser Permanente in Redwood City, California, alumna Dr. Christina Nguyen was on her way to work when she sprang into action to help save the life of a community member.

Bicyclists were waving people down and huddled around an unconscious woman who appeared blue and had shallow breathing.

Suspecting an opioid overdose, Nguyen asked one of the bystanders to call 911 and ran to her home a few steps away to grab Narcan, which she had on hand from her pharmacy residency training when she worked with patients who had an opioid use disorder. Nguyen knew from her training that it is better to be cautious when suspecting an opioid overdose, as the medicine would not harm the person if they were not overdosing.

Nguyen administered Narcan to the woman and then performed CPR until an ambulance arrived. She saw an immediate improvement in the woman's appearance and breathing. Just before the ambulance arrived, the woman woke up in a dazed state.

"Being able to step up when you see others in need is so important, especially because of my clinical expertise and training," Nguyen said. "You never know how much your individual actions can affect the rest of your community."




"I was simply doing what needed to be done, especially being in the right place at the right time with Narcan. This experience truly showcases how pharmacists' clinical training extends beyond dispensing medications."

Success in Residencies and Fellowships

81%
ASHP PGY1
Residency Match Rate

9
ASHP PGY2
Residency Matches



#3
for Match-rate
Success in CA

30
ASHP PGY1
Residency Matches

RALPHS GROCERY COMMITS \$50,000 FOR FUTURE COMMUNITY PHARMACISTS

As student pharmacists at Chapman University prepare for various career opportunities in a changing healthcare landscape, Ralphs Grocery Company has committed \$50,000 to establish an endowed scholarship for PharmD candidates interested in working in community pharmacy.

“Community pharmacists are the most accessible healthcare professionals, as anyone can walk into a pharmacy and receive care from a medication expert,” explained Dean Rennolds Ostrom. In recent years, the role of community pharmacists has expanded to include essential services such as point-of-care testing, immunizations, medication advisory services, and self-care recommendations for minor ailments. Ralphs Grocery Co. operates 76 pharmacies throughout its Southern California stores.

Ostrom expressed gratitude to Ralphs for the scholarship that will help students with a demonstrated interest in community pharmacy make CUSP’s top-notch education more affordable. “This scholarship demonstrates the commitment of CUSP toward training the next generation of community pharmacists through Ralphs Pharmacy,” he shared. “It also demonstrates Ralphs’ commitment to developing the very finest pharmacists to serve its diverse communities.”

At Ralphs, the community pharmacy allows pharmacists to treat every patient with individualized care. Patients can receive convenient and accessible care, allowing their pharmacists to develop a personal and emotional connection with each of their patients. Ralphs has been a partner of Chapman’s since the pharmacy school’s inception, first as a preceptor site for PharmD students, then serving on an advisory group and donating money towards scholarships.



“WE HOPE THAT STUDENTS WILL VIEW COMMUNITY PHARMACY NOT JUST AS A JOB BUT AS A **CRUCIAL PART OF THE HEALTHCARE COMMUNITY** WORKING TOGETHER TO HELP PEOPLE LIVE HEALTHIER LIVES.”

If Ralphs Grocery is inspiring you with its commitment to the future of community pharmacists, find out how you can make a positive impact on Chapman students by donating today.




HIGH IMPACT RESEARCH

With 18,200 square feet of state-of-the-art lab space and 7 clinical sites, our researchers drive impact in eight defined research areas. Our researchers discover new therapies in pediatric care, oncology, and other patient needs that will shape the future of healthcare solutions.



Young Woo Nam, PhD

A winner of the Career Development Award from the American Heart Association, Nam’s research focuses on the structural biology and electrophysiology of ion channels, particularly the KCa2.2 and KCa2.3 SK channels, which play a critical role in cardiac function. His work challenges the treatment of atrial fibrillation to advance our understanding of the structural and functional dynamics of these ion channels, enabling better drug design.



Sun Yang, PhD

Yang has touched many lives through her research as a pediatric oncologist. Recently, she was awarded a \$150,000 Opportunity Pool Grant from the MPRINT Hub, supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, to investigate the role of vitamin D in the gut microbiome of pediatric oncology patients. Yang splits her time between her clinic site, Children’s Hospital of Orange County, and her lab at Chapman.



Sherry Wang, PhD

Focusing on pharmacoepidemiology and health service research for addiction, cardiovascular disease, and COVID-19, Wang’s research addresses inequities in opioid prescribing, treatment disparities, and patient safety. Wang received a \$250,000 NIH AIM-AHEAD grant to explore the ethical implications of AI in healthcare, in order to foster equitable access for patients to resources, particularly for vulnerable populations.



Jennifer Totonchy, PhD

Totonchy has been invited to serve as a member of the NIH’s HIV Coinfections and HIV-Associated Cancers Study Section. Her research focuses on Kaposi Sarcoma Herpesvirus (KSHV), particularly its infection mechanisms in oral lymphoid tissues and B lymphocytes, to study viral tegument proteins and their impact on B cell physiology. Her work has implications for preventing and treating KSHV-associated diseases.



Gary Fong, PharmD

Fong’s research evaluates the potential impact of rezafungin in reducing healthcare costs and improving outcomes for underserved patient populations. Melinta Therapeutics awarded Fong a \$19,836 grant to investigate candidemia and antifungal resistance, and the Society of Infectious Diseases Pharmacists awarded him a \$2,500 Educational Grant to develop interactive modules for clinicians to assess the environmental impact of antimicrobial choices.



CITTERIO RECEIVES TWO EARLY INVESTIGATOR AWARDS

Both the **Endocrine Society** and the **American Association of Colleges of Pharmacy** recognized Citterio for her early-career contributions in 2024.

Dr. Cintia Citterio has been honored with two awards for her outstanding contributions to hormone-related research.

The Endocrine Society named Citterio as one of five recipients for their 2024 Early Investigator Award, recognizing her significant role in advancing our understanding of hormone-related conditions.

Citterio was honored with the American Association of Colleges of Pharmacy (AACP) New Investigator Award for her proposal titled “Molecular Pathogenesis of Thyroid Cystinosis and New Therapeutic Approaches.” This competitive award offers \$11,000 to exceptional early-career pharmacy faculty members, making her one of only four pharmacy researchers across the United States to receive this recognition in 2024.

Early investigator awards are designed to support the development of early-career investigators and acknowledges Citterio’s work in uncovering complex endocrine conditions. Endocrinologists are crucial in addressing intricate health issues such as diabetes, obesity, infertility, bone health, and hormone-related cancers. Citterio has enhanced the scientific community’s comprehension of these conditions but also holds promise for future advancements in treatment and patient care.

Citterio’s research primarily focuses on the molecular mechanisms leading to thyroid disorders and the biochemistry behind thyroid hormone formation. Her goal is to understand the molecular basis of these diseases to improve diagnosis and treatment. Her research findings have been published in over 20 publications and form the foundation of her currently funded K01 award from the NIH-NIDDK. She has received numerous accolades for her research, including the 2022 Excellence in Endocrinology award from the Committee on Diversity and Inclusion of the Endocrine Society. Additionally, she has been invited to speak at various national and international conferences and research institutions.

Dr. Citterio’s research delves into the molecular causes of thyroid cystinosis, a disorder that impairs the body’s ability to manage the amino acid cystine, leading to organ damage, including the thyroid gland. Her work shows promise for identifying new therapeutic approaches to manage this condition, with outcomes that will likely have ripple effects, paving the way for future research and discoveries.

CHAPMAN SECURES GOLD ANTIMICROBIAL STATUS

Dr. Amy Kang secured gold status for the Antimicrobial Stewardship Committee at Harbor-UCLA. This status, awarded by the California Department of Public Health (CDPH), is reserved for programs that demonstrate exemplary practices and have impactful community outcomes. Kang, an Assistant Professor of Pharmacy Practice, secured this award as the co-chair of the committee at Harbor-UCLA Medical Center.

Kang’s work at her practice site, Harbor-UCLA Medical Center, is supported by Chapman University School of Pharmacy, where we take pride in being committed to excellence in pharmacy. Kang’s integration of practice, research, and providing educational rotation sites through CUSP at Harbor-UCLA allows for both faculty and students to contribute to community health and professional practice.

The GOLD status is valid for three years, through May 31, 2027.



NATIONAL FOUNDATION FOR INFECTIOUS DISEASES NAMES GOAD PRESIDENT

Dr. Goad is the first pharmacist in history to hold this position.

Dr. Jeff Goad has been named President of the 2024-25 Board of Directors of the National Foundation for Infectious Diseases.

Goad, who coordinates and teaches courses in travel medicine, immunizations and parasitology, is a nationally recognized expert on travel medicine and immunization.

He co-founded the International Society of Travel Medicine Pharmacists Professional Group and has served as president of the California Immunization Coalition and the California Pharmacists Association. He was a guest on the National Foundation for Infectious Diseases’ podcast on July 3.

REVOLUTIONIZING ALZHEIMER'S TREATMENT, ONE BARRIER AT A TIME

Dr. Rachita Sumbria, an Associate Professor within the Biomedical and Pharmaceutical Sciences department, is making waves in 21st century understanding of Alzheimer's disease. 2024 was Sumbria's year, as she was awarded 2 NIA grants as well as a Woman of Distinction for Chapman University.





In a significant stride towards understanding and combating Alzheimer's disease (AD), Dr. Sumbria's lab has secured two substantial grants from the National Institute on Aging (NIA). These grants aim to explore innovative therapeutic strategies and deepen our understanding of the disease's pathology.

The first grant, an R21 award titled "The impact of obesity-induced hepatic amyloid beta dysregulation on Alzheimer's disease pathology," focuses on the relationship between obesity and the liver's regulation of amyloid beta, a protein closely linked to AD. Dr. Sumbria's lab will receive \$216,701 out of the total \$405,849 grant to investigate how obesity affects the liver-brain axis in Alzheimer's. This research could potentially uncover new therapeutic strategies for this devastating disease.

The second grant, an NIH R01 award worth \$1.71 million over the next five years, builds on Dr. Sumbria's previous successes in modifying erythropoietin (EPO) to cross the blood-brain barrier (BBB). This project aims to develop EPO as a therapeutic for AD, addressing challenges such as limited BBB penetration and hematopoietic side effects. The innovative approach involves fusing EPO with a monoclonal antibody (MAb) against the transferrin receptor (TfR) to enhance BBB penetration and reduce side effects. The funds will support dose-escalation and safety studies in various AD models and investigate the molecular pathways modulated by TfRMAB-EPO. Preliminary data suggest that this BBB-penetrating EPO has superior therapeutic and hematologic indices compared to EPO alone.

Dr. Sumbria's previous research has laid a strong foundation for these new projects. Her work includes a review titled "Alcohol as a Modifiable Risk Factor for Alzheimer's Disease-Evidence from Experimental Studies," which examined how alcohol could influence AD progression through brain-related mechanisms and alcohol-induced liver injury. Additionally, her lab has studied chronic alcohol consumption in APP/PS1 models with reduced hepatic LRP-1 expression, leading to increased brain amyloid beta and behavioral changes. This suggests that hepatic LRP-1 is a critical regulator of brain amyloidosis in alcohol-dependent Alzheimer's disease.

Dr. Sumbria's innovative approach to AD research, particularly her work on EPO's ability to modulate AD-related pathways and its neuroprotective effects, holds great promise. The findings from her current projects may establish a clinically feasible method for sustainable EPO delivery to the AD brain, potentially transforming the landscape of AD therapeutics.



UNLOCKING MYSTERIES TO RARE DISEASE


Zhang receives \$434,000 to alleviate symptoms

Dr. Miao Zhang has been awarded \$434,024 by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. This funding will support Zhang's groundbreaking project "Channelopathy of KCa2.3 and Zimmermann-Laband syndrome," aimed at unraveling the complexities surrounding Zimmermann-Laband syndrome 3 (ZLS3).

Zimmermann-Laband syndrome 3 is a rare genetic disorder that displays distinctive physical and developmental traits, including gingival enlargement and intellectual disabilities. Recent research has shown a connection between ZLS3 and mutations in the KCa2.3 channels, leading to greater sensitivity to calcium ions within these channels. Zhang and his team will continue to explore the underlying mechanisms of this heightened sensitivity by categorizing mutations based on their locations and potential impacts on channel function.

The study hopes to discover treatments that can counteract the dysfunctional KCa2.3 channels and potentially alleviate symptoms associated with ZLS3. Researchers also hope to pave the way for innovative therapeutic interventions tailored to the unique molecular signatures of ZLS3.

In addition, this project will explore the potential of existing drugs and compounds to inhibit the mutant KCa2.3 channels. Leveraging FDA-approved medications and compounds currently in clinical trials, the team will assess existing drugs and their ability to modulate the channel activity observed in ZLS3. This approach would allow for repurposing or identifying novel compounds, which would further advance the scientific understanding and therapeutic interventions for this genetic condition.



IMPROVING CORNEAL TRANSPLANTS

Sharma funded by NEI to understand MG53

Dr. Ajay Sharma has received a grant from the National Eye Institute for his project, "Targeting the multicellular process of corneal regeneration and vascularization to enhance outcome of cornea transplantation". He, alongside investigators at other institutions, will test the effect of topical application of a recombinant protein Mitsugumin 53 (MG53) on enhancing the success of corneal transplants in patients with high risk of rejection.

The goal is to assess whether recombinant MG53 alone or when used in combination with the currently used immunosuppressants can enhance the outcomes of corneal transplant. The studies will also investigate the mechanism of action of MG53. Sharma will be specifically involved in testing the ocular residency time, ocular penetration and ocular tolerability of a gel-based formulation of recombinant MG53.

The results of these studies can potentially pave the way for the future clinical use of this promising therapy for corneal transplant.



The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ADVANCING HEALTHCARE EQUITY WITH SPANISH-SPEAKING PATIENTS

The American Society of Health-System Pharmacists Foundation has awarded Dr. Jennifer Ko the Pharmacy Leadership Scholars Grant for her project, “Fostering Patient-Pharmacist Concordance with Patients Who Speak Spanish”.

In an effort to bridge the gap in healthcare for Spanish-speaking patients, a new study titled “Fostering Patient-Pharmacist Concordance with Patients Who Speak Spanish” aims to investigate the impact of language concordance (LC) and concordance on health beliefs regarding medication-taking (CMT) between pharmacists and Spanish-speaking patients. This research will seek to understand how these factors influence patient trust, hoping to enhance clinical pharmacy services and improve health outcomes for Hispanic populations.

The study, led by Dr. Ko in collaboration with Dr. Jerika Lam, Dr. Richard Beuttler, and Dr. Emmanuelle Schwartzman, will focus on developing and validating a survey tool in Spanish to assess CMT. By analyzing the relationship between LC and patient trust, the research hopes to provide valuable insights that will aid in the creation of training materials designed to foster concordance in clinical pharmacy services.

This study will expand our understanding of how language concordance affects the patient-clinician relationship beyond merely relaying information. It posits a strategy to improve health outcomes by achieving concordance in health beliefs surrounding medication-taking, a goal that can be employed in diverse contexts. By optimizing the patient-pharmacist relationship through multiple dimensions of concordance, the study aims to positively impact healthcare outcomes for patients disproportionately affected by health disparities.

The primary objective of this study is to evaluate patients’ attitudes and perceptions on CMT among Spanish-speaking patients, specifically by developing and validating a survey tool that assesses CMT in Spanish. A secondary objective is to evaluate if patient-pharmacist Spanish LC is related to patients’ trust in pharmacists. Through this comprehensive approach, the research endeavors to better understand and enhance the patient-pharmacist relationship, ultimately contributing to improved health outcomes in Hispanic populations.




PACIFIC COAST PATIENT SAFETY CONFERENCE



Dedicated to shaping policy and culture, the Pacific Coast Patient Safety Conference brings together patient safety experts from across the West Coast. With over 100 professionals spanning pharmacy, medicine, nursing, and academia, the conference fosters collaboration and discussion on emerging trends across healthcare disciplines. This boutique-style gathering offers a unique opportunity for professionals from diverse practice settings to connect, exchange ideas, and drive initiatives in patient safety, quality, and risk management.

Held in San Diego, the 2024 conference yet again broke attendance records. The 2025 conference will take place from February 28 to March 1 in Santa Barbara, CA. Attendees in California will have the opportunity to earn up to 10 Continuing Education (CE) units.




Personal and Inspirational Advocacy

Founding member of Patients for Patient Safety, Sue Sheridan, spoke of the devastating consequences of preventable patient errors within the healthcare system. The gravity of her story served as a strong reminder of the importance of patient safety initiatives and humanized the conference’s mission.



Exploration of AI and Automation in Healthcare

A significant portion of the conference explored the challenges and opportunities of adopting artificial intelligence and intelligent automation in healthcare. Panels led by Dr. Emily Do, Mr. Robert Imhoff, and Dr. Elizabeth Rebo offered insights into how AI can benefit daily workflows while addressing the complexities of its integration. Real-world case studies were implemented into their presentations and became dispersed into conversation throughout the conference.



Interdisciplinary and Collaborative Focus

The power of teamwork in healthcare was present throughout the educational programming of the conference, particularly through the session “Dynamic Duo: Pharmacy-Nursing Partnership in the Crusade for Patient Safety.” Emphasizing the importance of collaboration in improving processes such as barcode medication administration compliance, reducing cabinet overrides, and standardizing infusion concentration standards. The discussions demonstrated how interdisciplinary efforts can directly impact patient outcomes and safety.

JOIN CUSP CONNECT

Your one stop shop for all things career, professional networking, and giving to the next generation of Chapman Panthers.

CUSP Connect welcomes:

- Students
- Alumni
- Preceptors
- Hiring Managers



Scan to learn more and join!

